GlassScriptPhysician profile
Peter J Parker
NPI 1598783789
$7,487.98
in general payments reported to CMS, 2019-2025
28 companies · $1,358 in 2025
The $1,358 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2020: $754 · 2021: $1,087 · 2022: $1,111 · 2023: $854 · 2024: $1,359 · 2025: $1,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,517 · Consulting Fee: $38.57 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,517.46 |
| Consulting Fee | $38.57 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,394.77 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,366.71 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,067.18 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $961.70 | 2019-2025 | Airsupra, Tezspire |
| Novartis Pharmaceuticals Corporation | $602.33 | 2019-2025 | |
| Leo Pharma INC. | $375.74 | 2022-2025 | Adbry |
| Genentech USA, INC. | $268.49 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $235.75 | 2020-2025 | Takhzyro, Glassia |
| Pfizer INC. | $230.43 | 2019-2024 | |
| Amgen INC. | $189.71 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $103.91 | 2021 | |
| Abbvie INC. | $100.86 | 2021-2023 | |
| Ars Pharmaceuticals Operations, INC. | $80.58 | 2025 | Neffy |
| Optinose US, INC. | $73.89 | 2019-2025 | |
| Galderma Laboratories, L.P. | $52.92 | 2025 | Nemluvio |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $49.41 | 2019 | |
| Biocryst US Sales Co., LLC | $43.63 | 2024 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.57 | 2020 | |
| Adma Biomanufacturing LLC | $38.57 | 2024-2025 | |
| Octapharma USA, INC. | $31.13 | 2019 | |
| Organon LLC | $28.67 | 2025 | Vtama |
| Incyte Corporation | $28.46 | 2021 | |
| Potrero Medical, INC. | $28.03 | 2023 | |
| Shire North American Group INC | $24.66 | 2019 | |
| Cycle Pharmaceuticals INC | $23.15 | 2025 | Sajazir |
| Eyevance Pharmaceuticals LLC | $17.88 | 2021 | |
| Hikma Pharmaceuticals USA | $17.84 | 2025 | Ryaltris |
| Bio Products Laboratory USA, INC. | $8.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.